1-[4-(3-cyclopentyl-1,2,4-oxadiazol-5-yl)-piperidin-1-yl]-4,4,4-trifluoro-butan-1-one | 1352079-22-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-[4-(3-cyclopentyl-1,2,4-oxadiazol-5-yl)-piperidin-1-yl]-4,4,4-trifluoro-butan-1-one
• 英文别名: 1-[4-(3-Cyclopentyl-1,2,4-oxadiazol-5-yl)-1-piperidyl]-4,4,4-trifluoro-butan-1-one；1-[4-(3-cyclopentyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl]-4,4,4-trifluorobutan-1-one
• CAS: 1352079-22-1
• 化学式: C₁₆H₂₂F₃N₃O₂
• 分子量: 345.365
• InChiKey: VCBIAUIZNRZANE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.81
• 拓扑面积：
  59.2
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  N'-羟基环戊烷甲脒 在 盐酸 、 1-羟基苯并三唑 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 0.16h， 生成 1-[4-(3-cyclopentyl-1,2,4-oxadiazol-5-yl)-piperidin-1-yl]-4,4,4-trifluoro-butan-1-one
  参考文献：
  名称：

  Ethionamide Boosters. 2. Combining Bioisosteric Replacement and Structure-Based Drug Design To Solve Pharmacokinetic Issues in a Series of Potent 1,2,4-Oxadiazole EthR Inhibitors

  摘要：

  Mycobacterial transcriptional repressor EthR controls the expression of EthA, the bacterial monooxygenase activating ethionamide, and is thus largely responsible for the low sensitivity of the human pathogen Mycobacterium tuberculosis to this antibiotic. We recently reported structure-activity relationships of a series of 1,2,4-oxadiazole EthR inhibitors leading to the discovery of potent ethionamide boosters. Despite high metabolic stability, pharmacokinetic evaluation revealed poor mice exposure; therefore, a second phase of optimization was required. Herein a structure-property relationship study is reported according to the replacement of the two aromatic heterocycles: 2-thienyl and 1,2,4-oxadiazolyl moieties. This work was done using a combination of structure-based drug design and in vitro/ex vivo evaluations of ethionamide boosters on the targeted protein EthR and on the human pathogen Mycobacterium tuberculosis. Thanks to this process, we identified compound 42 (BDM41906), which displays improved efficacy in addition to high exposure to mice after oral administration.

  DOI：

  10.1021/jm200825u

文献信息

• FLUORALKYLCARBONYL-OXADIAZOLES
  申请人：Universite de Droit et de la Sante de Lille 2

  公开号：US20140309238A1

  公开（公告）日：2014-10-16

  The present invention relates to compounds of Formula (I), wherein R1 is chosen among the following radicals: (II); (III); (IV), (V), (VI) (VII) and n=1 or 2 and m=1 or 2 with the proviso that m=2 when R1 is (VIII). The present invention also relates to the use thereof as drugs, more particularly in the treatment of mycobacterial infections and more particularly in the treatment of tuberculosis.

  本发明涉及式（I）的化合物，其中R1选自以下基团：（II）、（III）、（IV）、（V）、（VI）、（VII），n=1或2，m=1或2，但当R1为（VIII）时，m=2。本发明还涉及其作为药物的用途，特别是在治疗分枝杆菌感染，尤其是在治疗结核病方面的用途。
• 1, 2, 4 - OXADIAZOLE DERIVATIVES AS ETHR INHIBITORS FOR USE IN THE TREATMENT TUBERCULOSIS
  申请人：Université de Droit et de la Santé de Lille 2

  公开号：EP2771338A2

  公开（公告）日：2014-09-03
• US8962658B2
  申请人：——

  公开号：US8962658B2

  公开（公告）日：2015-02-24
• [EN] COMPOUNDS HAVING AN ETHR INHIBITING ACTIVITY - USE OF SAID COMPOUNDS AS DRUGS - PHARMACEUTICAL COMPOSITION AND PRODUCT CONTAINING SAID COMPOUNDS<br/>[FR] COMPOSÉS PRÉSENTANT UNE ACTIVITÉ D'INHIBITION D'ETHR, UTILISATION DESDITS COMPOSÉS EN TANT QUE MÉDICAMENTS, COMPOSITION PHARMACEUTIQUE ET PRODUIT CONTENANT LESDITS COMPOSÉS
  申请人：UNIV LILLE II DROIT & SANTE

  公开号：WO2013060744A2

  公开（公告）日：2013-05-02

  The present invention relates to compounds of Formula (I), wherein R1 is chosen among the following radicals : (II); (III); (IV), (V), (VI) (VII) and n= 1 or 2 and m=1 or 2 with the proviso that m=2 when R1 is (VIII). The present invention also relates to the use thereof as drugs, more particularly in the treatment of mycobacterial infections and more particularly in the treatment of tuberculosis.
• Ethionamide Boosters. 2. Combining Bioisosteric Replacement and Structure-Based Drug Design To Solve Pharmacokinetic Issues in a Series of Potent 1,2,4-Oxadiazole EthR Inhibitors
  作者：Marion Flipo、Matthieu Desroses、Nathalie Lecat-Guillet、Baptiste Villemagne、Nicolas Blondiaux、Florence Leroux、Catherine Piveteau、Vanessa Mathys、Marie-Pierre Flament、Juergen Siepmann、Vincent Villeret、Alexandre Wohlkönig、René Wintjens、Sameh H. Soror、Thierry Christophe、Hee Kyoung Jeon、Camille Locht、Priscille Brodin、Benoit Déprez、Alain R. Baulard、Nicolas Willand

  DOI：10.1021/jm200825u

  日期：2012.1.12

  Mycobacterial transcriptional repressor EthR controls the expression of EthA, the bacterial monooxygenase activating ethionamide, and is thus largely responsible for the low sensitivity of the human pathogen Mycobacterium tuberculosis to this antibiotic. We recently reported structure-activity relationships of a series of 1,2,4-oxadiazole EthR inhibitors leading to the discovery of potent ethionamide boosters. Despite high metabolic stability, pharmacokinetic evaluation revealed poor mice exposure; therefore, a second phase of optimization was required. Herein a structure-property relationship study is reported according to the replacement of the two aromatic heterocycles: 2-thienyl and 1,2,4-oxadiazolyl moieties. This work was done using a combination of structure-based drug design and in vitro/ex vivo evaluations of ethionamide boosters on the targeted protein EthR and on the human pathogen Mycobacterium tuberculosis. Thanks to this process, we identified compound 42 (BDM41906), which displays improved efficacy in addition to high exposure to mice after oral administration.